Why the study?
Does aliskiren reduce mean arterial blood pressure in sodium-depleted marmosets?
Does aliskiren reduce mean arterial blood pressure in sodium-depleted marmosets?
The structural modification of renin inhibitors led to the discovery of aliskiren, an orally active agent that dose-dependently reduces blood pressure in primates.
Answers are grounded in this paper and cite their sources.
May support progression to human trials; leaves open clinical translation of oral renin inhibition from primate models.
Due to its function in the rate limiting initial step of the renin-angiotensin system, renin is a particularly promising target for drugs designed to control hypertension, a growing risk to health worldwide. Despite vast efforts over more than two decades, no orally efficacious renin inhibitor had reached the market. As a result of a structure-based topological design approach, we have identified a novel class of small-molecule inhibitors with good oral blood-pressure lowering effects in primates. Further lead optimization aimed for improvement of in vivo potency and duration of action, mainly by P2' modifications at the hydroxyethylene transition-state isostere. These efforts resulted in the discovery of aliskiren (46, CGP060536B, SPP100), a highly potent, selective inhibitor of renin, demonstrating excellent efficacy in sodium-depleted marmosets after oral administration, with sustained duration of action in reducing dose-dependently mean arterial blood pressure. Aliskiren has recently received regulatory approval by the U.S. Food and Drug Administration for the treatment of hypertension.
No takes yet. Share an insight, caveat, or question.
Maibaum et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: